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PeT with a non-internalizing Vector
Gregory W. Severin1,2,3*, Lotte K. Kristensen4, Carsten H. Nielsen4, Jesper Fonslet1, 
Andreas I. Jensen1, Anders F. Frellsen1, K. M. Jensen1, Dennis R. Elema1,  
Helmut Maecke5, Andreas Kjær 4, Karl Johnston6 and Ulli Köster6,7
1 Hevesy Laboratory, DTU Nutech, Technical University of Denmark, Roskilde, Denmark, 2 Department of Chemistry,  
Michigan State University, East Lansing, MI, United States, 3 Facility for Rare Isotope Beams, Michigan State University,  
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140Nd (t1/2  =  3.4  days), owing to its short-lived positron emitting daughter 140Pr 
(t1/2 = 3.4 min), has promise as an in vivo generator for positron emission tomography 
(PET). However, the electron capture decay of 140Nd is chemically disruptive to macro-
cycle-based radiolabeling, meaning that an in vivo redistribution of the daughter 140Pr 
is expected before positron emission. The purpose of this study was to determine 
how the delayed positron from the de-labeled 140Pr affects preclinical imaging with 
140Nd. To explore the effect, 140Nd was produced at CERN-ISOLDE, reacted with 
the somatostatin analogue, DOTA-LM3 (1,4,7,10- tetraazacyclododecane, 1,4,7- tri 
acetic acid, 10- acetamide N - p-Cl-Phecyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-
Lys-Thr-Cys)d-Tyr-NH2) and injected into H727 xenograft bearing mice. Comparative 
pre- and post-mortem PET imaging at 16 h postinjection was used to quantify the 
in vivo redistribution of 140Pr following 140Nd decay. The somatostatin receptor-positive 
pancreas exhibited the highest tissue accumulation of 140Nd-DOTA-LM3 (13% ID/g 
at 16 h) coupled with the largest observed redistribution rate, where 56 ± 7% (n = 4, 
mean ± SD) of the in situ produced 140Pr washed out of the pancreas before decay. 
Contrastingly, the liver, spleen, and lungs acted as strong sink organs for free 140Pr3+. 
Based upon these results, we conclude that 140Nd imaging with a non-internalizing 
vector convolutes the biodistribution of the tracer with the accumulation pattern of 
free 140Pr. This redistribution phenomenon may show promise as a probe of the cellular 
interaction with the vector, such as in determining tissue dependent internalization 
behavior.
Keywords: in vivo generator, 140nd, 140Pr, internalization, positron emission tomography, DOTa-lM3
inTrODUcTiOn
The demand for long-lived positron emitting radiolanthanides is growing due to the success of 
targeted internal radiotherapy with 177Lu, and the promise of other therapeutic lanthanides such 
as Auger electron emitters 165Er, and 135La or combined beta-/Auger electron emitters such as 161Tb 
(1–5). Neodymium-140 (140Nd, t1/2 = 3.4 days) decays to praseodymium-140 (140Pr, t1/2 = 3.4 min) by 
FigUre 1 | The decay scheme of 140Nd and its daughter 140Pr.
2
Severin et al. 140Nd DOTA-LM3
Frontiers in Medicine | www.frontiersin.org July 2017 | Volume 4 | Article 98
electron capture with no emission of gamma photons (Figure 1) 
(6). Because 140Pr has a 51% positron branch (Emean = 1.07 MeV) 
and a short half-life, the pair has potential for long-lived posi-
tron emission tomography (PET) tracing of pharmaceuticals. 
Together as a so-called in  vivo generator (7, 8), they provide 
a high positron yield with lanthanide labeling chemistry and 
a parent half-life that is suitable for monoclonal antibody, nano-
particle, and peptide imaging (9, 10). In this light, it is interesting 
to pursue development of 140Nd to investigate how the delayed 
positron emission from 140Pr affects medical imaging, and how 
it can be exploited.
The radionuclide 140Nd is non-standard in radiopharmacy, 
but can be produced in a variety of methods: via (p,2n) reac-
tions on naturally monoisotopic praseodymium-141 (11), 
3He bombardment of natural cerium (11–13), or by spallation 
processes on tantalum (14). Due to the relatively lower volatiliza-
tion temperature of the rare earths (compared to tantalum), it 
is possible to extract the spallation-induced radiolanthanides by 
thermal diffusion and separate them by mass, e.g., at the on-line 
separator ISOLDE at CERN (15, 16). In principle, this leads 
to the highest possible specific activity for radiochemistry and 
has been successfully employed in previous experiments with 
radiolanthanides (3, 17, 18). The (p,2n) production method is 
attractive for future developments because it is a reaction that 
is reachable by biomedical and hospital cyclotrons. However, 
it requires very high purity praseodymium starting material 
(without neodymium contamination), and a robust lanthanide 
separation technique in order to achieve radiolabeling with high 
specific activity.
When considering 140Nd for PET, its value for direct imaging 
hinges upon the chemical and kinetic profile of the positron 
producing daughter nuclide 140Pr. Previous reports show that 
the EC decay of DOTA-bound 140Nd is highly efficient at releas-
ing the daughter 140Pr from the chelate, making it available for 
further interactions as a Pr3+ cation (13). Praseodymium and 
neodymium have remarkably similar chemistry, and under the 
right conditions Pr3+ could be predicted to re-bind a free chelator 
after being released. However, an activation barrier to stable 
binding between lanthanide ions and DOTA precludes room 
temperature chelation of the Pr3+ daughter. Other chelators such 
as DTPA are not inhibited by an activation barrier and may fare 
better at retaining the daughter praseodymium. The mobility 
of the daughter praseodymium determines how different the 
distribution of the tracer-bound parent is from the distribution 
of the unbound daughter, the evaluation of which will determine 
the value of 140Nd/140Pr with functionalized DOTA in vivo. The 
current set of experiments serves as a preliminary investigation 
into the 140Nd/140Pr in vivo PET generator.
In order to create the appropriate scenario to test 140Nd/140Pr, 
the somatostatin receptor was selected as the target. The reason for 
this is threefold. First, somatostatin analogs are already employed 
clinically with the therapeutic radionuclide 177Lu (19) and the 
diagnostic radionuclides 64Cu (20) and 68Ga, where a long-lived 
positron emitting lanthanide could prove useful in dose determi-
nations. Second, the depth of research into somatostatin receptors 
has led to the development of well-established internalizing vec-
tors (21), such as DOTATATE, and non-internalizing vectors (22) 
such as DOTA-LM3 (23, 24). And third, the receptor is expressed 
in the pancreas, but not in many other tissues: thereby providing 
a test-tissue with more realistic perfusion than xenograft tumors. 
In the present study, testing was performed with DOTA-LM3 
anticipating that the redistribution of praseodymium would be 
most evident with a targeting vector that remained located on the 
surface of the targeted cells.
Herein, we present the results from 140Nd-DOTA-LM3 PET 
quantifications in H727 xenograft tumor-bearing mice before 
and after euthanasia. The pre- and post-mortem images represent 
the daughter and parent radionuclide distributions, respectively. 
As positrons are only emitted by the daughter, PET scanning only 
reveals the parent distribution in the absence of biological pro-
cesses that differentiate the vector bound parent from the daugh-
ter. We also show verification of the dislocation (also referred 
to as de-labeling) of 140Pr from DOTA-LM3 by radio-HPLC. 
Furthermore, ex vivo biodistributions from 140Nd-DOTA-LM3 
and 140Nd as the free ion are used to show the source and sink 
organs for the free praseodymium daughter.
MaTerials anD MeThODs
general
All water was 18 MΩ-cm MilliQ purified and was used to pro-
duce all aqueous solutions. Hydrochloric acid solutions were 
prepared from concentrated HCl (TraceSelect, Sigma).
Production of 140nd
A 55 g/cm2 tantalum foil target was irradiated by a 1.4 GeV proton 
beam, creating a multitude of radioactive and stable spallation 
products. The product nuclei, lanthanides in particular, diffused 
from the ≈2,000°C target to a ≈2,000°C tungsten surface ion-
izer. The ions were extracted at 30 kV and mass-separated with a 
70° sector magnet (1.5 m mean bending radius). The A = 140 
beam was implanted into two Zn-coated gold foils. The zinc, 
totaling 2–3 mg had been electrodeposited onto the gold foils over 
3Severin et al. 140Nd DOTA-LM3
Frontiers in Medicine | www.frontiersin.org July 2017 | Volume 4 | Article 98
approximately 0.5 cm2. The entire procedure is nearly identical 
to the methodology recently described for projects collecting 
Tb isotopes at ISOLDE (3, 17).
radiochemistry
The following methodology was carried out two times with 
small variations between each run.
The zinc layer containing 140Nd was etched briefly with aq. 
HCl (200  µL, 2  M), and the resulting solution was diluted to 
2.2  mL with aq. HCl (2  M). This was heated to 98°C, cooled, 
and passed over AG1x8 anion exchange resin (300 mg, Biorad, 
200–400 mesh, initially formate-form) packed in a 4  mm 
internal diameter (ID), fritted polypropylene column (Supelco) 
that had been prepped by three times sequential washing with 
water (3× bed volume), 2  M HCl (3× bed volume), and 6  M 
HCl (3× bed volume), finishing with equilibration in 2 M HCl. 
The resin has a high affinity for [ZnCl4]2− ions in 2 M HCl (25) 
and was intended to remove any zinc impurity from the 140Nd. 
An additional 0.5  mL of 2  M HCl was used to rinse residual 
140Nd from the column, and the entire effluent was collected and 
adjusted to pH 5–6 with aq. ammonium acetate (1  M, pH 7) 
and aq. ammonium hydroxide (28%, TraceSelect, Sigma) to a 
final acetate concentration of roughly 200 mM. This solution was 
passed over a hydroxamate functionalized Waters CM resin bed 
(26) (100 mg, 4 mm ID) to trap the 140Nd and was washed with 
water (7 mL), then eluted with aq. HCl (600 µL, 0.1 M). The elu-
ent was kept as the stock 140Nd solution for further radiolabeling 
and formulation.
For the DOTA-LM3 preparation, 220  µL of the 140Nd 
stock solution was added to aq. ammonium acetate (780  µL, 
300  mM). Two productions were made, the first with 9  µg 
DOTA-LM3 (added from a stock solution of 1  mg/mL in 
water) and the second with 18 µg DOTA-LM3. The solution was 
heated in a sealed container to 95°C and incubated for 25 min. 
After cooling to room temperature, the labeling reaction was 
quenched with aq. DTPA (12 µL, 0.5 mM, pH 7) and let stand 
for 5  min. The solution was passed over a Waters C18 light 
sep-pak (prepped with 10 mL ethanol and 10 mL water) to trap 
the labeled product, rinsed with 1 mL water, and then eluted 
with 2 mL ethanol. The ethanol solution was taken almost to 
dryness (residual volume was approximately 50  µL) with the 
residual being diluted with 900  µL HEPES buffered isotonic 
saline (10 mM HEPES, 150 mM NaCl, pH 7.4) and was used 
directly for injections.
The neodymium “chloride” injections were prepared by dilut-
ing 100  µL of 140Nd stock (in 0.1  M HCl) with 390  µL HEPES 
buffered isotonic saline (10 mM HEPES), and neutralizing with 
10 µL 1 M Na-HEPES.
hPlc Verification of De-labeling  
and radioTlc for Determination  
of radiochemical Purity
Samples of 140Nd-DOTA-LM3 were injected onto a reverse-phase 
C-18 (Luna 3uC18(2)(n) 100 A 100 × 2 mm 3 μm, Phenomenex) 
column at a flow rate of 0.5 mL/min starting from 0% acetonitrile 
in water, and reaching 100% over a 15 min gradient. Elution was 
monitored with a radio detector. The entire effluent was collected 
in 1  min intervals (500  µL each) and quantified 4  days after 
collection by liquid scintillation counting on a HIDEX 300 SL 
spectrometer.
RadioTLC was performed by spotting 1 µL of the DOTA-LM3 
solutions (before and after C-18 purification) onto aluminum-
backed silica TLC sheets. The sheets were eluted in 10% (w/v) 
aq. CH3COONa:CH3OH (1:1). Unreacted 140Nd remained at the 
origin, and 140Nd-DOTA-LM3 moved to Rf ~0.5.
PeT imaging and Ex Vivo Biodistributions
NCI-H727 lung carcinoid cancer cells (ATCC CRL-5815, LGC 
Standards) were cultured in RPMI-1640 media supplemented 
with 10% fetal bovine serum and 1% penicillin-streptomycin 
(Invitrogen) at 37° C and 5% CO2. Cells in their exponential growth 
phase and at 80–90% confluence were harvested by trypsinization 
and resuspended in 1:1 media and matrigel (BD Biosciences) 
at 5 ×  107 cells/mL. Subcutaneous tumors were established in 
female NMRI nude mice (Taconic, Denmark) by inoculation of 
5 ×  106 cells in 100  µL on each flank above the hind limbs in 
the subcutaneous space. All animal experiments were performed 
under a protocol approved by the National Animal Experiments 
Inspectorate of Denmark.
Longitudinal small animal PET/CT imaging (Inveon Multi-
modality PET/CT scanner, Siemens) was performed with 
NCI-H727 tumor bearing mice injected intravenously with 
3.3–4.3 MBq 140Nd-DOTA-LM3 (n = 8) or 2.7–3.1 MBq 140Nd- 
chloride (n = 3) in 150 µL. Mice were anesthetized with sevoflu-
rane (Abbott Laboratories) during injection and PET/CT imag-
ing. PET data was acquired for 600 s in list mode at 1, 3, and 16 h 
after injection. The mice were sacrificed after the 16 h time-point 
and a PET acquisition was performed 2 h post-mortem. Images 
were reconstructed using a 3D maximum a posteriori algorithm 
with CT based attenuation correction. CT images were acquired 
with the following settings: 300 projections, 65 kV, 500 µA, and 
400 ms exposure, and reconstructed with an isotropic voxel size 
of 105  µm. Image analysis was performed using the Inveon 
Software (Siemens). Region of interests (ROIs) were drawn man-
ually over the tumor regions and other organs based on the CT 
images and the uptake of 140Nd-DOTA-LM3 or 140Nd-chloride 
quantified as % injected dose per gram tissue (%ID/g).
Conventional ex vivo biodistribution was performed after the 
post-mortem scan. Tumors and organs were resected, weighted 
and the radioactivity was counted in a gamma counter (Wizard2, 
PerkinElmer).
resUlTs anD DiscUssiOn
isolation of 140nd at isOlDe, 
radiochemical Purification, and 
radiolabeling of 140nd-DOTa-lM3
140Nd was produced by 1.4  GeV proton induced spallation of 
tantalum at ISOLDE. The process for vaporization and ionization 
of lanthanides at the ISOLDE facility is well described (15), and 
proceeded without complication. The electromagnetic separa-
tion of proton rich A =  140 spallation products led to a total 
FigUre 2 | Effluent analysis of 140Nd-DOTA-LM3 in equilibrium with the 
daughter, 140Pr, from reverse-phase HPLC. The black line depicts the 
immediate radiotrace, showing the distribution of the daughter, 140Pr. The  
red bars give the LSC signal from collected fractions, 1 min each, analyzed 
>4 days after elution, illustrating the parent, 140Nd, distribution. Detector 
response is relative and scaled to the maximum for each trace.
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of about 530 MBq (in two productions) of >99% radionuclidic 
purity 140Nd in two Zn-coated gold foils. The 140Nd implanted 
foils were briefly etched (without fully dissolving the entire Zn 
layer) with aq. hydrochloric acid (HCl, 2 M) and the carrier Zn 
(approximately 1 mg Zn2+ in 2 mL 2 M HCl) was removed by 
passage over AG1x8 anion exchange resin. ICP-OES measure-
ment showed that Zn was completely adsorbed onto the resin, 
with <30 ng Zn remaining in the purified 140Nd stock solution 
(~60  MBq). 140Nd was concentrated by trap-and-release on a 
small mixed-bed hydroxamate/carboxylate-functionalized resin. 
Trapping was only efficient after heating the solution for several 
minutes at 95°C, indicating that the 140Nd may not have been 
completely dissolved during the initial Zn etching. When the 
2 M HCl etch solutions containing the Zn were heated prior to 
purification, the trapping on the hydroxamate/carboxylate resin 
exceeded 99% efficiency. The release of 140Nd from the resin was 
accomplished by elution with aq. HCl (600 µL, 0.1 M) at 98% 
efficiency.
The eluted 140Nd was reacted with DOTA-LM3 in ammonium 
acetate buffer (300 mM, pH 4.8), and after 30–60 min at 95°C 
radioTLC indicated that 140Nd-DOTA-LM3 had formed in a 
75% radiochemical yield. Quenching with DTPA and C-18 
sep-pak purification led to an ultimate combined radiochemical 
yield and recovery of 60% in HEPES-buffered saline (pH 7.4). 
RadioTLC after C-18 purification indicated >95% radiochemical 
purity of 140Nd-DOTA-LM3. The production, purification, and 
labeling procedure was performed twice, where the amount of 
peptide relative to radioactivity was selected based upon titra-
tion. Although it would have been ideal to have all samples at 
identical specific activity, it was not possible, and in this case, 
the final radiolabeled specific activities for 140Nd-DOTA-LM3 
were 5.0 and 2.5  MBq/nmol, each with sufficient activity for 
injection of four mice (see below).
140Nd in an unchelated form was prepared for injection by 
pH adjustment of the eluted 140Nd stock solution with sodium 
HEPES and diluted to a final formulation in pH 7.4, 150 mM 
NaCl, and 10 mM HEPES. Characterization of the 140Nd chemi-
cal species was not performed, and it is herein referred to as 
“140Nd-chloride” for convenience.
hPlc-Traces of 140nd DOTa-lM3
Purified 140Nd-DOTA-LM3 was analyzed on reverse-phase 
HPLC to highlight the parent-daughter dechelation effect. The 
relative quantifications of the HPLC effluent are shown overlaid 
in Figure 2. The product 140Nd-DOTA-LM3 eluted at 7.9 min, 
which agreed with the equilibrated liquid scintillation counter 
(LSC) trace, confirming >95% radiochemical purity of the 
140Nd-DOTA-LM3. It should be noted that parent-daughter 
transient equilibrium was reached before the LSC samples were 
counted, meaning that the LSC signal was representative of 
the parent 140Nd elution profile. In contrast, the online radio-
detector trace demonstrated the daughter 140Pr behavior. This 
is because the detector was more sensitive to gamma radiation 
arising from positron annihilation after 140Pr decay, and because 
of the relatively low abundance of penetrating radiation arising 
from 140Nd decay. Here, 140Pr was shown to elute with the solvent 
front with an elevated baseline between the solvent peak and 
elution of the parent 140Nd-DOTA-LM3. Since the 140Pr3+ eluted 
faster than the radiolabeled peptide, the solvent front peak was 
evidence of the formation of 140Pr3+ in the injected solution, and 
the elevated baseline showed the in situ formation and washout 
of 140Pr3+ from 140Nd decaying on the column. From the trace, 
it was evident that the release of 140Pr from DOTA-LM3 after 
140Nd decay is >95% efficient, matching the observations of 
Zhernosekov and co-workers (13). Furthermore, the column 
behavior illustrated the expected in  vivo behavior: a rapid 
redistribution of the positron-emitting daughter after the decay 
of the parent.
Ex Vivo Biodistributions of 140nd-DOTa-
lM3 and 140nd-chloride
Eight mice bearing dual-flank NCI-H727 lung carcinoid tumors 
were injected with 3–4 MBq 140Nd-DOTA-LM3: four at a specific 
activity of 5 MBq/nmol and four at 2.5 MBq/nmol. A further three 
tumor-bearing mice were injected with 3  MBq 140Nd-chloride. 
PET quantifications were obtained at 1, 3, and 16 h postinjection. 
After the last scan the animals were euthanized, and following 
equilibration of the daughter, the mice were rescanned. Finally, 
the animals were dissected, and tissue samples were weighed and 
counted.
For the unbound 140Nd-chloride injections, the ex vivo bio-
distribution (16  h) showed high levels of accumulation in the 
lungs, spleen and liver, and to a lesser extent bone and tumor 
(Figure 3). This is a typical biodistribution for free +3 oxidation 
state radiolanthanides [for femur and liver vs. tumor, see, Ref. 
(27)] and for other hard radiometals [e.g., see, Ref. (24)]. The 
tissues with high accumulation of 140Nd were also expected to 
accumulate released 140Pr, owing to the chemical similarities bet-
ween praseodymium and neodymium. Thus, this biodistribution 
serves as a descriptor of which tissues we expect to exhibit “sink” 
behavior in the pre-mortem PET scans.
The ex vivo biodistribution of 140Nd-DOTA-LM3 was very 
distinct from that of 140Nd-chloride with the pancreas, a known 
FigUre 3 | Ex vivo biodistribution of 140Nd-DOTA-LM3 and 140Nd-chloride. 
Animals were euthanized 16 h after injection of 3.3–4.3 MBq 140Nd-DOTA-
LM3 (5.0 MBq/nmol, 0.5 nmol injected, n = 4), 140Nd-DOTA-LM3 (2.5 MBq/
nmol, 1 nmol injected, n = 4) and 2.7–3.1 MBq 140Nd-chloride (n = 3). Organ 
counting commenced after parent/daughter equilibrium was achieved (2 h 
after euthanasia). 140Nd-DOTA-LM3 quantifications give the “source” 
distribution for 140Pr in the 16 h positron emission tomography studies, and 
140Nd-chloride qualitatively describes the “sink” behavior. Data are depicted 
as mean ± SEM.
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somatostatin receptor positive organ, being particularly interest-
ing (21). The pancreas was found to take up 140Nd-DOTA-LM3 
without accumulating the free radiometal (13% ID/g with high 
specific activity 140Nd-DOTA-LM3, compared to 0.1% ID/g 
with the free 140Nd3+). Therefore, in the PET study, the pan-
creas was expected to have a lower signal in the pre-mortem 
140Nd-DOTA-LM3 scans compared to the post-mortem scans. 
The liver, spleen, and lungs had the opposite behavior, accumu-
lating the free radiometal but not the peptide, and were expected 
to have a higher signal in the pre-mortem scans than in the 
post-mortem.
Fani et  al. showed that in comparing the biodistribution of 
68Ga-NODAGA-LM3, 68Ga-DOTA-LM3, 64Cu-NODAGA-LM3, 
and 64Cu-CBTE2A-LM3, tumor uptake relative to the pancreas, 
stomach, and kidney is highly variable depending on the metal 
and chelator used (23, 28). In the current work, we injected 
300 pmol (5 MBq/nmol) or 600 pmol (2.5 MBq/nmol) in order 
to get enough signal for the PET scans. For the biodistributions 
from Fani et  al., 10  pmol was injected, and blocking was per-
formed with 200 nmol of excess DOTA-LM3. The overall effect of 
the blocking was to reduce the uptake in sst2 expressing tissues, 
which is exactly what was observed between the higher and lower 
specific activity injections of the current study: a modest reduc-
tion in the uptake in sst2 expressing tissues relative to the kidney, 
and overall faster excretion.
Based upon the ex vivo biodistribution, the tumors had 
an intermediate behavior, weakly concentrating both the free 
140Nd and the labeled peptide, meaning that the PET signal was 
expected to change little between the pre- and post-mortem scans 
(i.e., washout of 140Pr from the tumor volume could be compen-
sated by uptake of 140Pr from the bloodstream). This behavior is 
in many ways an undesirable outcome, because signals arising 
from the tumors can be attributable to both the free metal ions 
and the targeted peptide. Future work with a different vector/
target system could give a result with a simpler interpretation. 
Nevertheless, the pancreas remains an interesting tissue within 
the present set of experiments.
PeT studies show Tissue Dependent 
redistribution of 140Pr after 140nd Decay
Positron emission tomography data were analyzed to quantify 
the 140Pr signal from the tumors, pancreas, kidney, lung, and liver 
(Table 1). The PET signals for the tumors are given as the percent 
of the injected signal per gram (%IS/g) (Figure 4). This unit is 
non-standard and is described further in the Supplementary 
Material. %IS/g was chosen for two reasons: first because the 
PET scans quantify the redistributed daughter 140Pr, not the 
140Nd-tracer, and second because the data were not corrected for 
point spreading due to extensive positron range. This means that 
there is a substantial partial volume distortion when converting 
from annihilation signal (%IS/g) to tracer concentration (%ID/g), 
and that the well-counter based ex vivo biodistribution is not 
directly comparable to the post mortem PET results. A discus-
sion of the partial volume effect due to the high energy positrons 
from 140Pr is included in the Supplementary Material. The tumor 
time-activity curve shows that in this model (as expected from 
the ex vivo biodistribution) very little redistribution is observed. 
For the present case, the tumor was known to accumulate the 
trivalent lanthanide to some small degree (from the Nd-chloride 
injection data above), meaning that 140Pr3+ produced by decay 
in the tumor region had some tendency to remain. In other 
organs, however, due to the dechelation effect, there was a 
dramatic change in the PET signal in the pre- and post-mortem 
imaging quantifications. The redistribution effects are displayed 
in Figure 5 as the ratio of the mean organ signal between the 
post-mortem, and pre-mortem (16 h) images. This effect is most 
evident in the pancreas and liver for the high specific activity 
injections, where the decrease in liver signal is matched by an 
increase in the pancreas signal, confirming the behaviors of the 
peptide and free metal observed in the ex vivo biodistribution.
It should be noted that the injected mass of the tracer had 
a large effect upon the PET quantifications and ex vivo biodis-
tribution (Figures  4 and 5). This indicates that the receptor-
specific accumulation was becoming saturated as the injected 
mass increased from 0.5  nmol (5.0  MBq/nmol) to 1  nmol 
(2.5 MBq/nmol). This saturation behavior is non-desirable for 
probing the internalization behavior of the peptide as non-
specific interactions begin to dominate the tracer distribution.
Figure  6 shows an example PET/CT reconstruction, quali-
tatively illustrating the redistribution effect. The most striking 
differences in the images between the daughter distribution 
(16 h, left panels) and the parent distribution (post-mortem, right 
panels) are seen in the liver, lungs, and pancreas. As expected, 
the 16  h pre-mortem PET images more closely reflected the 
biodistribution observed for the free 140Nd-chloride injections, 
while the post-mortem images showed the biodistribution for 
the intact 140Nd-DOTA-LM3 tracer.
The most important result from the PET imaging was the 
pancreatic signal. In this case, in the pre-mortem image, it was 
FigUre 5 | Ratio of the post-mortem positron emission tomography (PET) 
signal to the pre-mortem (16 h) PET signal for each tissue. Tissues with ratios 
greater than unity release 140Pr into circulation faster than they absorb it. 140Pr 
is trafficked away from the site of 140Nd decay. The pancreatic signal from the 
140Nd-chloride images was masked by the high liver signal, prohibiting reliable 
quantification.
FigUre 4 | Positron emission tomography (PET) signal in tumors as  
a function of time after injection with 3.3–4.3 MBq of 140Nd-DOTA-LM3 or  
2.7–3.1 MBq of 140Nd-chloride. Values are presented as %ID/g and depicted  
as mean ± SEM (140Nd-DOTA-LM3, n = 8 each and 140Nd-cloride, n = 6). 
Animals were anesthetized with sevoflurane during the 600 s PET 
acquisitions.
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difficult to delineate the pancreas due to the elevated-background 
in the liver. This is despite the fact that the ex vivo biodistribu-
tion revealed that the pancreas contained 13%ID/g of the tracer: 
which should be easily distinguishable from the 3%ID/g of the 
liver. The discrepancy is resolved in the post-mortem imaging, 
where the accumulation of the tracer in the pancreas, and not 
in the liver, is apparent. The effects observed are consistent with 
a hypothesis that 140Nd-DOTA-LM3 localized on the surface 
of pancreatic cells (via non-internalizing interactions with the 
somatostatin receptor) releases 140Pr3+ into the blood stream, 
where it is quickly redistributed to the liver, spleen and lungs. In 
fact, results from the higher specific activity 140Nd-DOTA-LM3 
FigUre 6 | Pre-mortem [left (a,c)] and post-mortem [right (B,D)] positron 
emission tomography/CT scan of a mouse 16 h after injection with 2.9 MBq 
140Nd-DOTA-LM3 (5.0 MBq/nmol). The upper frames are shown with a 
different scale in order to allow visualization of the sink behavior of the liver 
and lungs. In the lower frames, a white circle is drawn over the pancreas 
(somatostatin receptor expressing) where the difference in the pre- and 
post-mortem pancreatic signal is due to rapid diffusion of 140Pr from the 
highly perfused pancreas into the blood stream. Data were acquired over 
600 s. Pre-mortem anesthesia was sevoflurane (Lu, lungs; Li, liver; Ki,  
kidney; Tu, tumor; Pa, pancreas).
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studies show that 56 ±  7% (n =  4, mean ±  SD) of the in  situ 
produced 140Pr washed out of the pancreas before decay.
For statistical analysis the pre- and post-mortem PET quan-
tifications were compared with a paired-difference two-tailed 
t-test. The tabulated data are presented in Table  1, along with 
the p values. In this case, the t-test was used to determine the 
significance of the absolute difference between the pre- and 
post-mortem signals in %IS/g. Admittedly, there are many ways 
to analyze these data, and in this case, the paired-difference test 
was selected because it adds to the statistical power by comparing 
the tissues in a single subject to themselves after intervention. 
Clearly from the p values in Table 1, the use of DOTA-LM3 as 
a tracer led to significant changes from the pre- to post-mortem 
images, while the non-targeted 140Nd-chloride remained largely 
unaltered. Of note in the free ion 140Nd-chloride injections, is that 
the only tissue with a statistically significant difference between 
the pre- and post-mortem quantification is the kidney, whereas 
in the targeted DOTA-LM3 images the only tissue lacking a 
significant difference was the muscle. The kidney is interest-
ing because in all cases the post-mortem signal was higher, by 
25–50% than the pre-mortem value. While it could be suggested 
that this is due to rapid excretion of 140Pr3+ from the kidney to the 
bladder in vivo, the fact that this is also observed with the 140Nd- 
chloride injections indicates that within the kidney the chemi-
cal form of the neodymium is not necessarily as a free cationic 
lanthanide. However, in all other tissues, the distribution of 140Nd 
from the 140Nd-chloride injections strongly resembles that of 
redistributed 140Pr.
The pancreatic washout reveals a potential benefit derived 
from the 140Pr’s delayed positron. Specifically, the degree of 
redistribution of 140Pr3+ may be affected by its location and 
access to blood flow. This means that the PET signal observed 
with 140Nd labeled vectors might be highly dependent on their 
cellular internalization status, as 140Pr3+ cations originating from 
decays occurring on the surface of the cell or in circulation may 
be transported away by the blood flow, whereas 140Pr3+ cations 
released from 140Nd decay inside of a cell have an additional 
diffusion barrier. A conceptual graphic demonstrating the idea 
is depicted in Figure 7. As many promising new classes of phar-
maceuticals, in particular nanoparticle drug formulations, gene 
therapy and targeted Auger emitting radionuclides, are expected 
to be most effective when internalized, a PET radiolabel for 
determining internalization would be a valuable tool for drug 
development.
general Discussion
When searching for long-lived PET radionuclides, the utility of 
140Nd is immediately evident in its half-life and lack of concurrent 
gamma emissions. However, due to the nature of the delayed posi-
tron from the short-lived daughter, it is important to understand 
how imaging may be affected by dechelation. The redistribution 
of 140Pr in the present case was clearly visible in the pre- and post-
mortem PET images. While the tumor signal was significantly 
changed, the magnitude of change was small which may preclude 
application. However, this behavior might be model dependent, 
and not general for all tumor types or locations. Nevertheless, 
the signals from the other tissues show the potential for using the 
daughter-delay to determine the in vivo internalization status of 
new probes, as highlighted by the pancreatic signal. These data 
support a hypothesis that in certain cases, PET imaging with 
140Nd provides a localized signal only if a vector is internalized. 
This capability may prove useful in future drug development 
where in vivo internalization is critical for drug action.
FigUre 7 | A conceptual drawing of the experimental hypothesis. A tracer (R), is labeled by DOTA-bound 140Nd which decays by electron capture (EC) to 140Pr.  
The resulting atomic rearrangement releases the daughter 140Pr from DOTA as a free ion. If 140Pr diffuses into the blood stream before decaying (upper path), it will  
be carried away and give a remote positron emission tomography (PET) signal. However, if there is a diffusion barrier such as a cell membrane or a lack of blood 
flow (lower path), the PET signal will remain localized to the tracer accumulation site.
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Overall, the statistical analysis proves that the images gener-
ated using a DOTA-based 140Nd/140Pr in  vivo generator are 
significantly altered from the true distribution of the tracer. With 
more development, it may be possible to use this technique to 
determine specific details of the interaction between the tracer 
and its molecular target. While the p-values are often less than 
the nominal 0.05 designation for statistical significance, practical 
significance is weakened by a large inter-subject variability. This 
means that further development in the 140Nd in  vivo generator 
system will, for the time-being, remain an invasive procedure 
relegated to pre-clinical drug development.
cOnclUsiOn
In this study, we showed that the non-internalizing tracer 
140Nd-DOTA-LM3 accumulates in the pancreas and releases 
140Pr3+ into the blood stream where it quickly redistributes to the 
liver and lungs. We hope that further work will lead to the devel-
opment of internalization sensitive PET probes using 140Nd as the 
radiolabel. The experimental set up described here with pre- and 
post-mortem imaging should facilitate that development as it 
allows direct quantification of the parent (140Nd, post-mortem) 
and daughter (140Pr, pre-mortem) in the same subject. The ability 
to determine the tissue-dependent internalization of pharmaceu-
ticals using PET would aid greatly in drug delivery designs where 
cellular internalization is crucial to drug action.
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